UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREPTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpor ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q4 2023 Earnings Conference Call February 28, 2024 4:30 PM ET Company Participants Francesca Nolan - Executive Director of Investor Relations and Corporate Communications Douglas Ingram - President and Chief Executive Officer Louise Rodino-Klapac - Executive Vice President, Chief Scientific Officer and Head of Research & Development Dallan Murray - Executive Vice President and Chief Customer Officer Ian Estepan - Executive Vice President and Chief Financial Officer C ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number : 001-14895 Sarepta Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 93-0797222 (State or other jurisdi ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Francesca Nolan - IR Director Douglas Ingram - President and CEO Louise Rodino-Klapac - EEVP, Chief Scientific Officer and Head of Research & Development Dallan Murray - EVP & Chief Customer Officer Ian Estepan - EVP & CFO Conference Call Participants Anupam Rama - JPMorgan Tazeen Ahmad - Bank of America Securities Gena Wang - Barclays Colin Bristow - UBS Brian Skorney - Baird Salveen R ...

BENJAMIN Living with Duchenne muscular dystrophy Other timed secondary endpoints: • Stride velocity 95th centile (SV95C) • 100-meter walk/run (100MWR) • Ascend 4 steps ©SAREPTA THERAPEUTICS, INC. 2023. ALL RIGHTS RESERVED. 5 ©SAREPTA THERAPEUTICS, INC. 2023. ALL RIGHTS RESERVED. 8 NSAA -3.29 (-8.28, 1.70) 0.1942 Overall Treatment Group ELEVIDYS t == Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREPTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 93-0797222 (State or other ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Francesca Nolan - IR Director Doug Ingram - President and CEO Louise Rodino-Klapac - EEVP, Chief Scientific Officer and Head of Research & Development Dallan Murray - EVP & Chief Customer Officer Ian Estepan - EVP & CFO Conference Call Participants Colin Bristow - UBS Brian Abrahams - RBC Capital Markets Tazeen Ahmad - Bank of America Gena Wang - Barclays Salveen Richter - Goldman Sa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREPTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 93-0797222 (State or other juris ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2023 Earnings Conference Call May 2, 2023 4:30 PM ET Company Participants Mary Jenkins – Associate Director-Investor Relations Doug Ingram – President and Chief Executive Officer Louise Rodino-Klapac – Executive Vice President, Head-R&D and Chief Scientific Officer Dallan Murray – Executive Vice President and Chief Customer Officer Ian Estepan – Executive Vice President and Chief Financial Officer Conference Call Participants Colin Bristow – UBS Gena Wang – Barcla ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14895 SAREPTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 93-0797222 (State or other juri ...